Influence of oral verapamil on glucoregulatory hormones in man

Harry Shamoon, P. Baylor, D. Kambosos, S. Charlap, S. Plawes, W. H. Frishman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We evaluated the effect of treatment with placebo or verapamil (320 mg/day) for 2 weeks on glucose-induced insulin secretion and hypoglycemia-stimulated counterregulatory hormone secretion in hypertensive patients. Verapamil treatment was associated with a significant reduction in diastolic blood pressure (P = 0.02 vs. placebo). During a hyperglycemic clamp (plasma glucose raised 125 mg/dl above basal level) maintained for 90 min, plasma insulin increased 4- to 5-fold (early) and then to values 8- to 10-fold above baseline (late). These increments were identical during placebo or verapamil treatment. The rates of glucose metabolized during each study also were similar, suggesting that no significant change in insulin action occurred during drug treatment. When plasma glucose was allowed to decline precipitously from hyperglycemic levels (220 mg/dl) to nadirs ranging from 42-77 mg/dl, plasma concentrations of glucagon, cortisol, epinephrine, and norepinephrine all increased; however, no consistent differences in the counter-regulatory hormone responses could be attributed to verapamil therapy. We conclude that physiologically effective drug concentrations of verapamil capable of influencing bloood pressure do not have a significant effect on secretion of glucoregulatory hormones in man.

Original languageEnglish (US)
Pages (from-to)536-541
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume60
Issue number3
StatePublished - 1985

Fingerprint

Verapamil
Hormones
Plasmas
Glucose
Placebos
Insulin
Blood Pressure
Drug therapy
Therapeutics
Glucose Clamp Technique
Blood pressure
Clamping devices
Glucagon
Hypoglycemia
Pharmaceutical Preparations
Epinephrine
Hydrocortisone
Norepinephrine
Pressure

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Shamoon, H., Baylor, P., Kambosos, D., Charlap, S., Plawes, S., & Frishman, W. H. (1985). Influence of oral verapamil on glucoregulatory hormones in man. Journal of Clinical Endocrinology and Metabolism, 60(3), 536-541.

Influence of oral verapamil on glucoregulatory hormones in man. / Shamoon, Harry; Baylor, P.; Kambosos, D.; Charlap, S.; Plawes, S.; Frishman, W. H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 60, No. 3, 1985, p. 536-541.

Research output: Contribution to journalArticle

Shamoon, H, Baylor, P, Kambosos, D, Charlap, S, Plawes, S & Frishman, WH 1985, 'Influence of oral verapamil on glucoregulatory hormones in man', Journal of Clinical Endocrinology and Metabolism, vol. 60, no. 3, pp. 536-541.
Shamoon H, Baylor P, Kambosos D, Charlap S, Plawes S, Frishman WH. Influence of oral verapamil on glucoregulatory hormones in man. Journal of Clinical Endocrinology and Metabolism. 1985;60(3):536-541.
Shamoon, Harry ; Baylor, P. ; Kambosos, D. ; Charlap, S. ; Plawes, S. ; Frishman, W. H. / Influence of oral verapamil on glucoregulatory hormones in man. In: Journal of Clinical Endocrinology and Metabolism. 1985 ; Vol. 60, No. 3. pp. 536-541.
@article{92febf1b100e4c15a31833315ac21865,
title = "Influence of oral verapamil on glucoregulatory hormones in man",
abstract = "We evaluated the effect of treatment with placebo or verapamil (320 mg/day) for 2 weeks on glucose-induced insulin secretion and hypoglycemia-stimulated counterregulatory hormone secretion in hypertensive patients. Verapamil treatment was associated with a significant reduction in diastolic blood pressure (P = 0.02 vs. placebo). During a hyperglycemic clamp (plasma glucose raised 125 mg/dl above basal level) maintained for 90 min, plasma insulin increased 4- to 5-fold (early) and then to values 8- to 10-fold above baseline (late). These increments were identical during placebo or verapamil treatment. The rates of glucose metabolized during each study also were similar, suggesting that no significant change in insulin action occurred during drug treatment. When plasma glucose was allowed to decline precipitously from hyperglycemic levels (220 mg/dl) to nadirs ranging from 42-77 mg/dl, plasma concentrations of glucagon, cortisol, epinephrine, and norepinephrine all increased; however, no consistent differences in the counter-regulatory hormone responses could be attributed to verapamil therapy. We conclude that physiologically effective drug concentrations of verapamil capable of influencing bloood pressure do not have a significant effect on secretion of glucoregulatory hormones in man.",
author = "Harry Shamoon and P. Baylor and D. Kambosos and S. Charlap and S. Plawes and Frishman, {W. H.}",
year = "1985",
language = "English (US)",
volume = "60",
pages = "536--541",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Influence of oral verapamil on glucoregulatory hormones in man

AU - Shamoon, Harry

AU - Baylor, P.

AU - Kambosos, D.

AU - Charlap, S.

AU - Plawes, S.

AU - Frishman, W. H.

PY - 1985

Y1 - 1985

N2 - We evaluated the effect of treatment with placebo or verapamil (320 mg/day) for 2 weeks on glucose-induced insulin secretion and hypoglycemia-stimulated counterregulatory hormone secretion in hypertensive patients. Verapamil treatment was associated with a significant reduction in diastolic blood pressure (P = 0.02 vs. placebo). During a hyperglycemic clamp (plasma glucose raised 125 mg/dl above basal level) maintained for 90 min, plasma insulin increased 4- to 5-fold (early) and then to values 8- to 10-fold above baseline (late). These increments were identical during placebo or verapamil treatment. The rates of glucose metabolized during each study also were similar, suggesting that no significant change in insulin action occurred during drug treatment. When plasma glucose was allowed to decline precipitously from hyperglycemic levels (220 mg/dl) to nadirs ranging from 42-77 mg/dl, plasma concentrations of glucagon, cortisol, epinephrine, and norepinephrine all increased; however, no consistent differences in the counter-regulatory hormone responses could be attributed to verapamil therapy. We conclude that physiologically effective drug concentrations of verapamil capable of influencing bloood pressure do not have a significant effect on secretion of glucoregulatory hormones in man.

AB - We evaluated the effect of treatment with placebo or verapamil (320 mg/day) for 2 weeks on glucose-induced insulin secretion and hypoglycemia-stimulated counterregulatory hormone secretion in hypertensive patients. Verapamil treatment was associated with a significant reduction in diastolic blood pressure (P = 0.02 vs. placebo). During a hyperglycemic clamp (plasma glucose raised 125 mg/dl above basal level) maintained for 90 min, plasma insulin increased 4- to 5-fold (early) and then to values 8- to 10-fold above baseline (late). These increments were identical during placebo or verapamil treatment. The rates of glucose metabolized during each study also were similar, suggesting that no significant change in insulin action occurred during drug treatment. When plasma glucose was allowed to decline precipitously from hyperglycemic levels (220 mg/dl) to nadirs ranging from 42-77 mg/dl, plasma concentrations of glucagon, cortisol, epinephrine, and norepinephrine all increased; however, no consistent differences in the counter-regulatory hormone responses could be attributed to verapamil therapy. We conclude that physiologically effective drug concentrations of verapamil capable of influencing bloood pressure do not have a significant effect on secretion of glucoregulatory hormones in man.

UR - http://www.scopus.com/inward/record.url?scp=0021962029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021962029&partnerID=8YFLogxK

M3 - Article

C2 - 3882735

AN - SCOPUS:0021962029

VL - 60

SP - 536

EP - 541

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -